By Frank Prenesti
Date: Monday 27 Jan 2020
(Sharecast News) - AstraZeneca said it had agreed to sell the global commercial rights to a range of hypertension treatments to Atnahs Pharma for up to $390m.
Abbvie boss blasts US tax regime | 21-Oct-2014 | Telegraph |
Drug company AbbVie takeover rival in £31bn bid | 18-Jul-2014 | Express & Star |
AbbVie to announce firm bid for Shire | 18-Jul-2014 | Telegraph |
AbbVie's raised proposal for Shire gets board ba... | 15-Jul-2014 | Guardian |
Shire set to accept £31bn bid from US rival AbbVie | 15-Jul-2014 | Express & Star |
No recent information was found.
No recent information was found.
Currency | US Dollars |
Share Price | $ 185.71 |
Change Today | $ 1.69 |
% Change | 0.92 % |
52 Week High | $216.66 |
52 Week Low | $154.79 |
Volume | 5,210,328 |
Shares Issued | 1,765.26m |
Market Cap | $327,826m |
Beta | 0.42 |
RiskGrade | 122 |
Strong Buy | 6 |
Buy | 11 |
Neutral | 9 |
Sell | 0 |
Strong Sell | 0 |
Total | 26 |
Time | Volume / Share Price |
16:00 | 667,945 @ $185.71 |
16:00 | 300 @ $185.74 |
15:59 | 3,000 @ $185.74 |
15:59 | 442 @ $185.71 |
15:59 | 105 @ $185.71 |
You are here: research